foxo4-dri senolytic human trial Peptide inhibitors targeting FOXO4-p53 interactions and inducing senescent cancer cell-specific apoptosis The disordered p53 transactivation domain

It works by blocking nerve signals, providing temporary relief from pain and discomfort

Small human trials have not revealed significant toxicity, but they also lack rigorous design and long-term surveillance

Enhances Cognitive Clarity: Some Europe studies suggest the peptide may boost mental clarity and cognitive performance, aiding memory and focus (8)

BPC 157 Peptide Capsules are administered orally, and its mechanism of action mainly includes the following aspects: Promote angiogenesis BPC 157 can significantly promote the expression of vascular endothelial growth factor (VEGF) and accelerate the formation of new blood vessels